| Dr Kenneth Emil Liffmann, MD | |
|
189 Summit Dr, Cranston, RI 02920-3616 | |
| (401) 944-5134 | |
| Not Available |
| Full Name | Dr Kenneth Emil Liffmann |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 189 Summit Dr, Cranston, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992015028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD03410 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kenneth Emil Liffmann, MD 189 Summit Dr, Cranston, RI 02920-3616 Ph: (401) 944-5134 | Dr Kenneth Emil Liffmann, MD 189 Summit Dr, Cranston, RI 02920-3616 Ph: (401) 944-5134 |
News Archive
Climate change could kill more than 500000 adults in 2050 worldwide due to changes in diets and bodyweight from reduced crop productivity, according to new estimates published in The Lancet. The research is the strongest evidence yet that climate change could have damaging consequences for food production and health worldwide.
Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute, in collaboration with King's College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells.
Nu Skin Enterprises, Inc. today announced that its board of directors declared a 9 percent increase in the quarterly cash dividend to $0.125 per share. Annually, this would increase the dividend to $0.50, up from $0.46 in the prior year. The increase begins in the first quarter and will be paid on March 17, 2010, to shareholders of record on Feb. 26, 2010.
BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.
› Verified 2 days ago
Aravind Narayan Mohandas, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 65 Sockanosset Cross Rd, Cranston, RI 02920 Phone: 401-886-4830 | |
Dr. Gerald Marsocci, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 725 Reservoir Ave, Ste 202, Cranston, RI 02910 Phone: 401-943-8824 Fax: 401-943-8854 | |
Dr. Joseph Anthony Latina, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1145 Reservoir Ave, Suite 302, Cranston, RI 02920 Phone: 401-946-2370 Fax: 401-943-1006 | |
Dr. Mohammed Abiri, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 725 Reservoir Ave, Ste 306, Cranston, RI 02910 Phone: 401-944-1052 Fax: 401-944-1053 |